Open AccessPB1862: BRUIN CLL‐313: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
Author(s) -
Jurczak W.,
Dartigeas C.,
Coscia M.,
Ganly P.,
AlJazayrly G.,
Wang C.,
Bao K.,
Leow C. C.,
Shahda S.,
Zinzani P. L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850300.53785.f4
Subject(s) - bruton's tyrosine kinase , chronic lymphocytic leukemia , bendamustine , ibrutinib , rituximab , medicine , ighv@ , gastroenterology , oncology , leukemia , lymphoma , tyrosine kinase , receptor